HomeNewsVideos

Itama Ranoraya aimed 80% to 100% growth in revenue and net profit

23 April 2021 05:27

JAKARTA. PT Itama Ranoraya Tbk (IRRA) set a target of 80% to 100% increase in revenue and net profit this year following the market launch of the new immunomodulatory product, Avimac, in Q2 2021.

The management said that the company would rely on auto-disposable syringes (ADS), apheresis machines for blood plasma, antigen tests, and the new product Avimac to attain the said objective. This was mentioned in the information disclosure in Indonesia Stock Exchange, Thursday (22/4).

As of Q1 2021, the company managed to score revenue of IDR 228.17 billion, soaring high by 754.1% compared to its Q1 2020 revenue of IDR 26.71 billion. Meanwhile, its net profit was recorded at IDR 20.91 billion. It also jumped up significantly by 853.6% year-on-year (yoy) compared to its net profit in Q1 2020, reaching only IDR 2.2 billion.

During the company’s Annual General Shareholders Meeting on Thursday (22/4), the company discussed the dividend distribution of 30% of last year’s net profit, equal to IDR 12 per share. The payment would be made by May 25, 2021, along with the scheduled cum and ex dividend on April 30 and May 3, 2021, as Pratoto Raharjo, the Financial Director of IRRA, disclosed in a press release on Thursday (22/4). (AM/ZH)

© 2024 - IDN Financials - All Rights Reserved.